AJP - Lung Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 294: L387-L398, 2008. First published December 27, 2007; doi:10.1152/ajplung.00330.2007
1040-0605/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/3/L387    most recent
00330.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mizgerd, J. P.
Right arrow Articles by Skerrett, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mizgerd, J. P.
Right arrow Articles by Skerrett, S. J.

INVITED REVIEW

ANIMAL MODELS OF HUMAN LUNG DISEASE

Animal models of human pneumonia

Joseph P. Mizgerd1 and Shawn J. Skerrett2

1Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, Massachusetts, and 2Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington


    ABSTRACT
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
Pneumonia is a medical and public health priority, and advances against this disease will require improved knowledge of biological mechanisms. Human pneumonia is modeled with experimental infections of animals, most frequently mice. Mouse models are leading to important discoveries relevant to pneumonia, but their limitations must be carefully considered. Several approaches to establishing pneumonia in mice have been developed, and each has specific strengths and weaknesses. Similarly, procedures for characterizing microbial and host responses to infection have unique advantages and disadvantages. Mice are not small humans, and the applicability of results from murine models to human disease depends on understanding the similarities and differences between species. Additional considerations such as mouse strain, microbe strain, and prior mouse-microbe interactions also influence the design and interpretation of experiments. Results from studies of pneumonia in animals, combined with complementary basic and translational studies, are elucidating mechanisms responsible for susceptibility to and pathophysiology of lung infection.

mice; lungs; inflammation; neutrophils


WORLDWIDE, ACUTE LOWER RESPIRATORY tract infections are the leading cause of premature death and are responsible for a greater burden of disease than cancer, heart attacks, or HIV/AIDS (57, 70). Infectious diseases are more problematic in poorer communities, but lower respiratory infections cause greater morbidity and mortality than any other infection across the socio-economic spectrum (57, 70). In the United States, there has been little or no improvement in rates of death due to pneumonia and influenza for the last 5 decades (4). Further medical and public health advances in this area will require improved knowledge of the underlying biology that results in these infections being so common and so severe.

The biology of lung infections is being elucidated in experiments using diverse approaches (91). Combinations of human population studies, experimental infections of animals, and in vitro analyses are essential to progress on this front. In this review, we discuss the use of experimental infections of animals to elucidate the biology of pneumonia in humans. For the purposes of this review, pneumonia will be defined as acute inflammation in the lung parenchyma induced by microbial infection of the air spaces (Fig. 1).


Figure 1
View larger version (132K):
[in this window]
[in a new window]

 
Fig. 1. Pneumonia in the human lung showing acute inflammation in the distal air spaces. Images were collected from autopsy slides of a 50-yr-old man with terminal bacterial pneumonia and widely disseminated adenocarcinoma. A is from an area of early pneumonia showing fluid, fibrin, and neutrophils in the air space and congestion of interstitial vessels. B is from an area of more well-established pneumonia showing dense neutrophil infiltration of the air space and vascular congestion. Images and pathological interpretations were courtesy of Dr. John J. Godleski (Brigham and Women's Hospital, Boston, MA). Original magnification was x200.

 
Diverse animal species provide useful information in pneumonia experiments. Animals without lungs, such as Caenorhabditis elegans, Drosophila melanogaster, or zebrafish, are often used in studies of host-pathogen interactions. While modeling pneumonia only indirectly at best, studies with such species have provided important information about innate immune responses to some of the microbes that cause pneumonia. Nonmammalian species such as birds are studied due to veterinary or zoonotic interest but relatively infrequently. The vast majority of pneumonia studies with animals are performed in mammals. Larger mammalian species, such as rabbits, dogs, and monkeys, are studied to facilitate some types of investigation (e.g., involving extensive physiological monitoring and supportive therapies). Another reason investigators rely on these larger mammalian species is their close phylogenetic relation to the human species. However, rodents and particularly mice are used in pneumonia studies far more frequently than any other animals. This review will focus on using mice to study pneumonia, although many points apply more broadly.

Mice are an important research tool for multiple reasons. Their small size and rapid reproductive rate are conducive to many of the practicalities of laboratory research. Inbred strains allow the study of genetically identical cohorts and facilitate genetic approaches to understanding molecular mechanisms of disease. Genetic engineering of mouse embryonic stem cells is now available to most investigators, and a wide variety of mice have already been generated with loss-of-function, gain-of-function, or reporter genes in their genome, many in cell-specific or condition-specific fashions. Because mice have become such a mainstay of biomedical research, new mouse studies benefit from the vast amount of existing literature regarding murine host defenses and immunology for comparison and from having many relevant resources such as recombinant mouse proteins or antibodies against mouse proteins readily available. With mice so widely appreciated by the biomedical community, we will not emphasize here the many general advantages of using them for experimental studies. Instead, we will discuss considerations particular to studying pneumonia in mice.


    THE FIRST PRACTICAL CONSIDERATION FOR STUDYING PNEUMONIA IN MICE: HOW TO GET MICROBES INTO THE LUNGS
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
Several methods have been developed to produce experimental pneumonia, each of which has its own advantages and disadvantages (Ref. 6; Table 1).


View this table:
[in this window]
[in a new window]

 
Table 1. Methods for inducing pneumonia in animals

 
Exposure to infected animals. Transmission of some respiratory pathogens via droplet nuclei or physical contact can be achieved by cohousing uninfected animals with experimentally inoculated seed animals (2, 26, 58, 90). This method has the attraction of mimicking the natural transmission of contagious infections, and passage of the infectious agent through the seed mice may enhance virulence, thereby reducing the infectious dose for secondary infection (135). The weak cough reflex in mice probably limits the transmission of respiratory pathogens by group housing, which may be most useful for natural murine pathogens. The disadvantages of this experimental design include the inability to control inoculum, time of infection, or the number of infected animals.

Exposure to aerosolized microorganisms. Many lower respiratory tract infections are acquired by the inhalation of infectious aerosols, including tuberculosis, legionellosis, Mycoplasma and Chlamydia infections, fungal pneumonias, and respiratory viral infections. Aerosol dissemination also is considered the most likely method of delivering a biological weapon, such as anthrax, smallpox, tularemia, or plague (8). The airborne mode of transmission can be mimicked by exposing mice to aerosolized microorganisms in whole-body or nose-only chambers (6, 11, 19, 46, 48, 55, 99, 115, 116, 122, 123). In whole-body exposure systems, animals are placed in fenestrated or mesh compartments within an enclosed chamber. A respirable aerosol, generated by one or more nebulizers designed to produce particles predominantly 1–4 µm in size, is drawn through the chamber by negative pressure. Total airflow is regulated to meet the ventilatory needs of the animals, and humidity can be controlled to optimize microbial viability. The duration of exposure is typically 30–60 min. The targeted inoculum is achieved by adjusting the concentration of microorganisms in the nebulizer. With nose-only systems, mice are positioned in restraining tubes such that only their snouts are exposed to the aerosol chamber. Exposure times are often shorter (5–15 min) with nose-only systems to minimize the restraint time. Whole-body exposure chambers are simpler to operate and less costly than nose-only systems and do not require restraint of the animals. On the other hand, nose-only systems do not coat the entire animal with the infectious agent and thus facilitate biocontainment and reduce the chance of secondary inoculation of experimental animals. Nose-only systems also feature smaller exposure chambers than whole-body systems and thus require smaller volumes of nebulized material to achieve targeted inocula than whole-body systems.

Aerosol exposure systems permit the simultaneous infection of large numbers of unanesthetized animals. The actual inoculum of organisms deposited in the lungs after aerosol exposure can be predicted from the concentration of microorganisms in the nebulizer, estimated by sampling the aerosol, or confirmed by quantitative culture of lung tissue from sentinel animals immediately after exposure (11, 55, 99). Microbial deposition in the lungs of simultaneously exposed animals can vary from as little as 10% to severalfold depending on the infectious agent and the aerosol system. The inhalation of aerosolized microorganisms results in symmetrical deposition throughout both lungs (10, 122). This permits efficient use of tissues from infected animals; as both lungs represent the same process, one lung can be used for one set of measurements and the other lung can be used for distinct purposes. Disadvantages of aerosol models of infection include the costly equipment that must be regularly maintained and tested and the potential exposure of laboratory personnel to airborne biohazards. Deposition of aerosolized organisms in the upper respiratory tract, on the eyes and pelt, and clearance to the alimentary tract may be a confounding factor in some infections (10, 11). Furthermore, some respiratory pathogens (such as Streptococcus pneumoniae and some respiratory viruses) are particularly sensitive to desiccation and/or oxygen toxicity and survive poorly when aerosolized. Finally, there is an upper limit of the inoculum that can be achieved by inhalation; higher dose infections can be achieved by bolus methods.

Direct endotracheal or endobronchial instillation. Direct inoculation of the lower respiratory tract can be achieved via transtracheal injection or peroral intubation (6, 10, 12, 22, 34, 53, 56, 78, 83). Both methods require general anesthesia. For transtracheal injection, the trachea is surgically exposed and then penetrated caudally with a 25- to 30-gauge needle. The microbial suspension is injected in a volume of 5–50 µl followed by air, after which the incision is sutured or stapled closed. For the peroral route, mice are suspended by their incisors in a semivertical position, and the trachea is accessed via the mouth using a blunt-tipped needle. Intubation can be guided by palpation or transillumination of the trachea (10, 83). With either the transtracheal or peroral approach, it is possible to advance a catheter into the left mainstem bronchus to cause unilateral infection. The peroral technique avoids the surgical wound required for transtracheal injection, which may elicit an acute phase response and cause animal discomfort but is more difficult to perform. Both methods have the advantage of permitting more precise dosing to the lungs of individual animals than other techniques. These methods model oropharyngeal aspiration and deliver a bolus of organisms to a localized area of lung parenchyma, resulting in a higher ratio of infecting organisms to phagocytes and other local defenses at the site of infection than is achieved with aerosol exposure (11, 83). Biocontainment is simpler and the necessary equipment less costly than with aerosol exposures. A caveat with endotracheal injection methods is that the inoculum of microorganisms is deposited predominantly in the lower lung zones in a nonuniform manner (10); this can lead to sampling error if some but not all of the infected lung tissue is processed for a given measurement. Drawbacks of direct instillation techniques include the requirement for general anesthesia, with attendant effects on host defenses and risk of death, and the staggered start time of the experiment, because each animal is infected individually. In addition, peroral intubation is associated with some contamination of the lower respiratory tract with oropharyngeal flora (53).

Intranasal instillation. Intranasal inoculation is a popular means of infecting mice with respiratory pathogens (32, 50, 54, 130, 138). For this technique, anesthetized mice are held in the vertical position, and the microbial suspension is deposited in the nares, after which a portion of the inoculum is aspirated into the lungs. Inhalation anesthetics such as isoflurane work best for intranasal inoculation, as the procedure is brief and a stable plane of anesthesia is desirable to minimize variations in the rate and depth of respirations. Inoculation volumes vary from 5–50 µl, but smaller volumes tend to remain localized in the upper respiratory tract. The major attraction of this method is its simplicity. This technique also may have particular relevance for modeling respiratory infections that involve both the upper and lower respiratory tract, such as viral, Mycoplasma, and Chlamydia infections. The major limitation of intranasal instillation is the highly variable deposition of microorganisms in the lungs, with inter-animal differences in microbial deposition often exceeding 10-fold (19, 22, 53). Sources of variability include expulsion of inoculation volume from the nose, diversion of the inoculum into the alimentary tract or paranasal sinuses, and variable depth and frequency of respirations during the required anesthesia. Aspirated material after intranasal inoculation is deposited stochastically and asymmetrically in both lungs, so that accurate measurements of colony-forming units and host responses generally require processing of all lung tissue. The infectious inoculum also is deposited in boluses of variable size, in contrast with the more uniform deposition achieved with aerosol inhalation. Intranasal instillation also may result in coaspiration of upper respiratory flora and microbial products that may elicit a confounding host response. Nasal instillation also may be a more potent stimulus to the mucosal immune system than aerosol exposure (48, 94).


    THE NEXT PRACTICAL CONSIDERATIONS: HOW TO GET INFORMATION OUT
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
Measuring the microbial burden in mouse lungs. The standard approach to measuring the microbial burden in the lungs and other tissues is quantitative culture. Organs are harvested from euthanized animals, homogenized, serially diluted, and dispersed on suitable media for incubation and subsequent enumeration of colony-forming units. In the case of viral infection, tissue homogenates are cultured on appropriate target cells for enumeration of plaque-forming units. In preparing specimens for quantitative culture, care must be taken to use diluents that preserve the viability of fastidious organisms. Pathogens with a tendency to clump, such as staphylococci and mycobacteria, may need to be dispersed sonically or with detergents to ensure that colony-forming units represent single organisms. Especially for intracellular infections, the tissue preparation should be certain to result in lysis of host target cells.

Detection of nucleic acids by real-time PCR has emerged as an alternative approach to measurement of microbial burden in host tissues. This method is particularly valuable with microorganisms that cannot be propagated in artificial media or in tissue culture, such as Pneumocystis, for which PCR has replaced quantitative microscopy for enumeration of cysts (2, 131). Nucleic acid amplification techniques also can be less cumbersome than tissue culture methods for enumerating viruses and chlamydiae (80, 132) and for quantitation of organisms that grow very slowly on artificial media, such as Mycoplasma and Mycobacteria. For pathogens that grow in mycelia, real-time PCR is a more sensitive indicator of microbial mass than quantitative culture (9). Nucleic acid amplification is very sensitive but may not differentiate viable from nonviable organisms.

Bioluminescence is another promising modality for measuring microbial burden (45, 100). This method is based on the detection of light produced by microorganisms that have been engineered to express a luciferase gene and its specific molecular substrate. Useful luciferases for this purpose have been cloned from fireflies, jellyfish, sea pansies, corals, beetles, and bacteria. Bioluminescence can be detected through several centimeters of tissue, and thus it is possible to detect light emitted from the lungs and other organs of mice by viable organisms expressing a luciferase reporter gene. This method has been used to detect bacterial, fungal, and viral infections in mice (Refs. 30, 45, 101; Fig. 2). The great advantage of this approach is the opportunity to quantify and localize microbial burden in living animals that can be imaged repeatedly over time, under brief anesthesia, to follow the course of infection or the impact of therapeutic interventions. The limitations of bioluminescence are the need to use a luciferase-expressing pathogen, the costly imaging system required, and the limited sensitivity and resolution of the current technology. It is expected that advances in this field will rapidly expand the potential applications of bioluminescence to the study of pulmonary infections.


Figure 2
View larger version (99K):
[in this window]
[in a new window]

 
Fig. 2. Bioluminescence imaging of microbial burden in mouse lungs. Luciferase-expressing Streptococcus pneumoniae were delivered to the lungs of mice, and light emission was captured using a bioluminescent imaging system. Some mice also received antibiotics, as indicated. Colors indicate a heat map of infection, with red representing greatest microbial numbers. Reprinted from Francis et al. (30) and used with permission.

 
Measuring the inflammatory response to microbes in the lungs. The acute inflammatory response includes neutrophil recruitment and pulmonary edema in humans (Fig. 1) as well as mice (Fig. 3). Both of these processes are essential determinants of outcome during pneumonia (71). Both can be measured in mice to elucidate mechanisms contributing to host defense and pathophysiology.


Figure 3
View larger version (76K):
[in this window]
[in a new window]

 
Fig. 3. Pneumonia in mouse lungs, showing neutrophil and edema accumulation in the alveolar air spaces using scanning electron microscopy (top) or light microscopy (bottom). Reprinted from Prince et al. (91) and used with permission.

 
Measuring neutrophils in infected lungs. In an uninfected lung, neutrophils are in the blood (with increased numbers marginated within the pulmonary capillaries compared with other blood vessels) but not the air spaces (24). However, within hours of infection, neutrophils begin to appear in the interstitial compartments and air spaces of the lungs (14, 72).

Perhaps the most widely used method for measuring neutrophil recruitment in the lungs is the enumeration of neutrophils recovered by bronchoalveolar lavage (BAL). This is usually accomplished by cannulating the trachea and injecting and withdrawing a buffered salt solution using a syringe. Some of the cellular contents of the air spaces are recovered by such lavage; the amount and type of materials recovered depend on the numbers of washes, volumes per wash, and characteristics of the solution used for washing (e.g., whether or not divalent cations are present or chelated). The numbers of cells and the percentage that are neutrophils can be determined. All neutrophils so recovered are presumed to have been in the air spaces and to be a reflection of the total quantity of emigrated neutrophils in the lung.

There are distinct strengths to BAL analyses of neutrophils. BAL is a very sensitive and easily quantifiable measure of airway inflammation. Cells including neutrophils recovered by BAL can be subsequently subjected to additional assays or analyses (e.g., flow cytometry). The BAL fluid recovered along with the cells contains other materials such as cytokines or microbes that can be measured to provide additional information about the state of the lungs being studied (albeit in a highly diluted state). However, limitations to BAL analyses should also be considered. The degree of consolidation in pneumonic lungs may influence lavage, with more consolidated regions being less efficiently sampled than healthier regions; if consolidation differs systematically among experimental groups, then sampling efficiency may also differ systematically. Differences in the "lavageability" of cells, due, for example, to cell-cell adhesion, can influence which cells are recovered by lavage; if factors that influence lavageability differ across experimental groups, then sampling efficiency may again differ systematically. By design, only air space neutrophils are sampled, so emigrated but subepithelial neutrophils will not be detected. Finally, no information about where in the tracheobronchial tree or alveoli the neutrophils were before lavage is available. However, due to the strengths detailed above, BAL is often a useful means for quantifying emigrated neutrophils in mouse lungs.

Perhaps the definitive method for quantifying neutrophils in the lungs is morphometric analysis. Neutrophils are morphologically distinct even in standard hematoxylin and eosin-stained sections from paraffin-embedded tissues, so quantifying neutrophils in histological sections is straightforward using stereological techniques. We usually rely on a microscope with a reflecting arm, but other specialized optical attachments or digital imaging with integrated software can be applied. Neutrophils are recognized as emigrated when observed in the air spaces or in the perivascular and peribronchial interstitium and lymphatics. Proper tissue preparation is critical (133); lungs fixed at a consistent transpulmonary pressure with buffered glutaraldehyde are comparably inflated across animals and stable for further processing. If potentially heterogeneous deposition of microbes is of concern, then an inert tracer such as colloidal carbon can be mixed with the suspension of microbes to identify regions of the lung that received the dose. As with all morphometric analyses, an appropriate sampling strategy is critical to collecting interpretable results (133), and the investigator quantifying slides must be blinded to the identities of the mice.

There are advantages to using a morphometric approach to quantify emigrated neutrophils in pneumonic mouse lungs. Neutrophils in all localizations of the lung can be discriminated, rather than only air space neutrophils, and neutrophils will be reliably registered regardless of lung consolidation, cell-cell adhesion, or other tissue and cell properties. Neutrophil emigration can be localized within the anatomical context, so variability across different lung lobes, distinct parts of the tracheobronchial tree, and other anatomic compartments can be discriminated. The sections prepared for morphometry are amenable to additional histological and morphometric analyses revealing other aspects of pulmonary pathology. There are also disadvantages. The morphometric approach is slow compared with other techniques for quantifying neutrophils, with results coming days to weeks instead of minutes to hours after the completion of the experiment. It is also labor intensive, with results requiring hours to days of focused attention rather than minutes to hours. However, if neutrophil recruitment is an outcome of particular interest, then morphometry provides insights not attainable with any other approach.

Other methods are also sometimes used to quantify neutrophils in the lungs. Neutrophils can be quantified in single cell suspensions collected after enzymatic digestion of the lungs. This does not measure emigrated neutrophils but rather all neutrophils in the lung sample. Lungs can be perfused before these analyses, but it is difficult to remove all intravascular neutrophils, especially during inflammation when many are firmly adherent to endothelial cells. Markers for neutrophil presence, such as myeloperoxidase activity, can be measured in lung homogenates. As above, this does not measure emigrated neutrophils but rather all neutrophils in the lung sample. Furthermore, the degree to which myeloperoxidase per neutrophil varies during granulopoiesis and inflammation can complicate interpretation.

Measuring pulmonary edema. There are many methods to measure pulmonary edema (86), but, in short, none are fully satisfactory. A poorly met need for investigators studying pneumonia in mice is a reliable, accurate, and precise measurement of edema in the lungs.

The liquid content of the lung can be measured, most often expressed as the ratio of the lung wet weight to dry weight (measured before and after desiccation). This technique reflects total lung liquid accumulation, but it is rather insensitive and has disappointing signal-to-noise ratios. Large differences between groups of mice with severe edema are discernible, but smaller differences, moderate edema, and regional heterogeneity in edema usually are not. Edema accumulation in the alveolar air spaces can be appreciated in lung sections using light microscopy, which can be quantified by morphometry. An advantage of this is that the sites of edema accumulation can potentially be discriminated, but the focal heterogeneity of edema accumulation can present a sampling challenge. Air space filling with protein-rich plasma exudate can also be measured by quantifying concentrations of total protein or plasma proteins such as albumin or IgM in BAL fluids. These methods are, again, rather insensitive since much pulmonary edema can accumulate without pronounced air space flooding.

More sensitive approaches involve tracers injected intravenously and then measured in the lungs. Different types of tracers can be measured using diverse techniques (e.g., radioactivity for radiolabeled albumin, ELISA for human albumin, or spectrophotometric absorbance for Evans blue dye). For all such tracer studies, intravascular tracer content must be differentiated from extravascular tracer content. One method is to measure tracer appearance in the BAL fluid (64). Another method is to perfuse the lungs with tracer-free solutions and measure what remains (139). Yet another method is to quantify the blood volume in the lung and subtract the intravascular tracer content from the total tracer content in the lungs (75, 76). None of these methods are direct measures of edema content but rather measures of the net accumulation of the tracer over a given time period. The timing of tracer injection relative to the time of infection and to the time of tissue collection is a critical determinant of the results; different timings will be necessary to elucidate different types of changes in biology contributing to net edema accumulation. The properties of the tracer are another critical determinant; tracers may interact with tissue proteins, transport proteins, or other factors in the blood or lungs that may cause them to accumulate or disappear from the lungs differently from the liquid surrounding them.

Pulmonary edema accumulation results from changes in many biological variables that exhibit distinct but interacting dynamics. Diverse techniques are available to measure determinants contributing to edema rather than edema accumulation per se. For example, microbes in the air spaces of mouse lungs alter both microvascular permeability and alveolar fluid clearance, each of which can be measured (18, 118, 136).

Measuring sequelae of inflammation. Physiological sequelae of pneumonia can be measured in mice. Spontaneous ventilation, measured in mice using plethysmography (e.g., using the Buxco system), appears to be disparately affected by lung infection in mice and in humans. Whereas human patients with pneumonia typically exhibit rapid shallow breathing, mice instead develop a breathing pattern with a decreased respiratory rate and little or no change in tidal volume, resulting in decreased minute ventilation (20, 75). Changes in lung mechanics in pneumonic mice can be measured using a ventilator (e.g., with the flexiVent system) and are generally consistent with those observed in human patients. For example, inflammatory injury during pneumonia decreases lung compliance in mice (75) as in humans. Arterial blood gases can be measured in mice similar to as in humans, with similar findings; severe pneumonia results in arterial hypoxemia and increased alveolar-arterial oxygen gradients (76, 118).

Noninvasive approaches. Noninvasive measurements are useful for characterizing the dynamic processes of infection and inflammation. Microbial burdens can be measured noninvasively using bioluminescence, as described above (Fig. 2). Bioluminescence can also be used as a noninvasive measurement of gene induction during pneumonia, using mice with luciferase-based promoter-reporter transgenes (101). Limitations described above for bioluminescent detection of microbes apply as well as the degree to which artificial promoters inserted into the chromatin in a nontargeted fashion accurately and specifically report transcription factor activity or endogenous gene expression. PET can be used to noninvasively image relative levels of glucose metabolism in tissue, which correlates with neutrophil recruitment during pneumonia (106). Limitations to PET imaging include the requirements for radioactive probes, the degree to which these probes are specific to biological processes of interest (e.g., glucose metabolism as an indicator of neutrophil recruitment), and millimeter-scale resolution. Pulmonary edema may be measured noninvasively, as with X-ray imaging of the human chest (on which the diagnosis of pneumonia is based). The small size of mice limits the utility of traditional X-ray analyses, but alternative imaging methods are being developed and refined (16, 25, 43, 95). MRI has been used to noninvasively characterize fluid accumulation in pneumonic mouse lungs (124), which offers micrometer-scale resolution but relatively low sensitivity. Contrast agents may improve MRI sensitivity (28) in future studies of infected lungs. Ventilation can be measured noninvasively, as described above. Perhaps the most common noninvasive measure used in such studies is body weight, which decreases during pneumonia compared with control mice (39, 119), likely due to changes in behavior and metabolism. Although ventilation and body weight are easily measured in mice, they are very indirect indicators of infection, inflammation, and their physiological sequelae.


    THE BIG CONCERN: A MOUSE IS NOT A HUMAN
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
Mice and humans differ in many important ways relevant to lung infection (Table 2). Differences in the structural anatomy of the murine respiratory tract compared with humans may influence the deposition and clearance of inhaled or aspirated microorganisms. The surface area of the nasal passages is proportionately much larger in mice than in humans and functionally more devoted to olfaction (94). The close apposition of the epiglottis to the soft palate prevents oral inhalation and renders mice obligate nose breathers (94). The tracheobronchial tree has fewer and less symmetrical branches in mice than in humans, and mouse airways terminate abruptly into alveolar ducts without intervening respiratory bronchioles (7, 128). The cellular composition of the murine tracheobronchial epithelium also differs from that of humans. The mouse airway has few mucous and serous cells, and the submucosal glands, which are common in human bronchi (81), are absent below the rostral trachea in mice (47, 85, 87). The absence of nerve endings in murine respiratory epithelium may account for the inability of mice to cough in response to mechanical stimulation of the airway mucosa (85).


View this table:
[in this window]
[in a new window]

 
Table 2. Select differences between mice and humans relevant to pneumonia

 
Species differences in the structure and function of airway epithelium are reflected in the secretory defenses of the lower respiratory tract. For example, the spatial distribution of lysozyme production, which helps maintain the sterility of the lower respiratory tract, differs in humans and in mice (114). In humans, lysozyme is secreted mainly by the serous cells of the bronchial submucosal glands. In mice, submucosal glands are absent from the conducting airways, and lysozyme is secreted predominantly by type II pneumocytes (114). The production of hypothiocyanite, another airway epithelial microbicide, appears to be lacking in mice. Unlike human respiratory epithelium, mouse tracheal epithelial cells do not express dual oxidases that generate hydrogen peroxide, a substrate for lactoperoxidase-catalyzed production of hypothiocyanite (79). In contrast, both human and murine airway epithelial cells express constitutive and inducible β-defensins with broad antimicrobial activity (107).

Local phagocytic defenses in the mouse lung also differ from those of humans in potentially important ways. Alveolar macrophages exhibit species differences in their capacity to ingest and kill bacteria and fungi and in their susceptibility to intracellular parasitism (36, 109). The roles of inducible nitric oxide synthase (iNOS) and the production of reactive nitrogen intermediates in the antimicrobial defenses of alveolar macrophages also appear to differ between mice and men. Whereas nitric oxide contributes prominently to the antibacterial functions of activated murine alveolar macrophages (126), iNOS is regulated differently in human cells, and its antimicrobial role in human alveolar macrophages remains an area of controversy (29, 42, 104).

Species differences also exist in the pattern recognition receptors that serve as the early warning system for activating pulmonary host defenses against infection. Toll-like receptors (TLRs), which recognize diverse pathogen-associated molecular patterns and are essential for triggering innate and adaptive immune responses, are highly conserved among vertebrate species, but the tissue expression and transcriptional regulation of TLRs differ somewhat in mice and humans (93). For example, TLR3 expression by human leukocytes is restricted to myeloid dendritic cells, but, in mice, TLR3 is strongly expressed by macrophages as well (93). Similarly, TLR9 is primarily expressed by plasmacytoid dendritic cells and B cells in human blood but is more broadly expressed by murine myeloid cells (93). TLR5 also may be differentially expressed by human and murine macrophages. Whereas human monocyte-derived macrophages and dendritic cells express TLR5 and respond to flagellin, murine bone marrow-derived macrophages and dendritic cells do not (67, 129). On the other hand, mouse alveolar macrophages express TLR5 and respond to flagellin (59, 84), but human alveolar macrophages have been reported to lack TLR5 (62). In addition to differences in tissue expression, the ligand specificities and affinities of TLRs and other pattern recognition receptors also differ in humans and mice. Human TLR2, but not mouse TLR2, distinguishes between tripalmitoylated and trilauroylated lipopeptides (33). Similarly, human TLR4 discriminates between pentacylated and hexacylated lipid A structures from Pseudomonas aeruginosa, whereas murine TLR4 does not (35). As a result, human cells respond poorly to the hexacylated lipopolysaccharide found in P. aeruginosa isolated from patients with cystic fibrosis, but these structures are strongly recognized by mouse cells (35). Murine TLR5 is more sensitive to the presence of flagellin than human TLR5 (3). Mouse and human TLR9 also recognize distinct CpG DNA motifs (38). There also are differences between humans and mice in the functions of non-TLR pattern recognition receptors. For example, human nucleotide binding and oligomerization domain protein 1 (Nod1), an intracellular receptor for bacterial peptidoglycan, recognizes a muramyl tripeptide, whereas the murine NOD1 is triggered by a muramyl tetrapeptide (21, 60). The development of humanized mice that express human receptors in place of the murine homologs is an exciting advance in the use of murine models for understanding the roles of these signaling pathways in human disease (112).

There are other differences in the inflammatory and immune responses in mice and humans that may affect pulmonary host defenses. Circulating neutrophil counts are lower in mice than in humans (36), and mouse neutrophils lack {alpha}-defensins (27). There is no murine homolog of IL-8, a CXC chemokine with a major role in neutrophil recruitment to sites of infection, although mice express homologs of other CXC chemokines, and CC chemokines in mice are similar to their human counterparts (117). The expression of matrix proteins that regulate the inflammatory response also differ in humans and mice (110). Natural killer cell activity is generally higher in murine than in human lungs, but there is substantial variability among strains of mice in this regard (36).


    OTHER WAYS IN WHICH EXPERIMENTAL DESIGN IMPACTS RESULTS AND INTERPRETATION
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
Although it may be obvious that a mouse is not a human, it is also evident that a mouse cannot be considered truly representative of mice. Different mouse strains demonstrate remarkably different responses to microbes in their lungs. For example, after identical infections of the respiratory tract with pneumococcus, some strains of mice (e.g., BALB/c) demonstrate no bacteremia and virtually no lethality, whereas other strains (e.g., C57BL/6 and DBA/2) demonstrate a modest bacteremia (hundreds of bacteria per milliliter of blood) with ~50% lethality, and still other strains (e.g., CBA/Ca, C3H/He, and SJL) develop severe bacteremia (millions of bacteria per milliliter of blood) with 100% lethality (31). Of a similar nature, C57BL/6 mice are more susceptible to Klebsiella infection of the lung than are 129/Sv mice, with identical initial infections resulting in log scale differences in bacteria/lung and all of the latter but virtually none of the former strain of mice developing bacteremia and dying (105). Whereas most mouse strains cannot be productively infected with Legionella pneumophila, A/J mice are particularly susceptible and permit replicative infection (12). Thus results of studies in a given mouse strain may or may not be generalizable beyond that strain, and roles of specific molecular pathways in mediating responses in pneumonic mouse lungs may be discernible in some mouse genetic backgrounds but not others. Of course, this "limitation" is also a great strength in the hands of geneticists. For example, distinct responses of inbred mouse strains led to the discovery that mammalian TLR4 triggered innate immune responses to bacterial lipopolysaccharide (89).

Prior interactions of mice with microbes may influence their immune responses to experimental infections. The pathogen-free barrier facilities in which most mice are raised for experiments limits variability in this regard and ensures that investigators can control whether or not mice are naïve to the pathogen of interest during experimental pneumonia studies. However, this environment is quite different from that experienced by other mice or humans, and it raises the risk of systematically influencing results. For example, to the degree that the "hygiene hypothesis" of immunodevelopment applies (103), the diminished pathogen exposures in barrier facilities may alter immune responses of research mice. Furthermore, the commensal microbes colonizing mucosal surfaces influence mammalian physiology and immunology (44), and commensal flora may differ among mice in experimental studies. For example, littermates of different genotypes may host different commensal populations if genotype influences colonization; mice within one inbred colony may have different commensals from other inbred colonies even if genotypes are identical or irrelevant to colonization; and mice in barrier facilities almost certainly have different commensals than do mice or humans that do not live within barrier facilities. The impact of such prior interactions with microbes on pneumonia studies in mice is poorly understood, but matching the prior interactions of control and experimental groups with microbes as best as possible seems advisable.

A main reason that mice have become such a common animal in experimental studies is that they are so readily accessible with specifically targeted genetic mutations. As with any studies using such mice, it must be remembered that the alteration of a single gene product can have complicated results. The prolonged deficiency of a gene product can change the utilization of alternative pathways, making roles for that molecule difficult to discern with such mice. For example, whereas acute inhibition of ICAM-1 by blocking antibodies or antisense oligonucleotides decreases neutrophil recruitment elicited by Gram-negative bacterial stimuli in mouse lungs, the genetic deficiency of ICAM-1 does not (51, 92). In addition, the prolonged deficiency of a gene product can lead to physiological changes that complicate experimentation. For example, CD18 deficiency in mice leads to a pronounced peripheral blood neutrophilia that hinders studies of neutrophil emigration except for when it is completely dependent on this molecule (74); discriminating different roles for CD18 in mediating neutrophil recruitment during different types of pneumonia cannot be accomplished simply by infecting CD18-deficient mice but requires a more complex experimental design (73). Finally, the transgenic systems used to modify gene expression in mice, such as transactivators or recombinases, can themselves have unexpected deleterious effects, independent of the genes they are designed to influence (113, 134).

Many of the same concerns described above as relevant to the mouse are also relevant to the microbe, resulting in different microbes within a single genus and species exhibiting differences in virulence during pneumonias in mice. Just as mouse strain is critical, so also is microbe strain. For example, several thousand S. pneumoniae of serotype 2 or 3 in the lungs result in bacteremia and death of mice, whereas S. pneumoniae of serotype 19 is unable to induce bacteremia after lung infection and results in a nonprogressive course unless tens of millions of bacteria are inoculated (13, 49). Just as prior experiences of the mice are a critical variable, so also is prior experience of the microbes. Culturing pathogens in a particular environment is sometimes essential to virulence, and prior animal passage often increases microbial pathogenicity during lung infection (17, 63, 96, 97, 102, 137). Thus the characteristics of that particular microbe are as important to consider as the characteristics of that particular mouse for experimental studies of pneumonia.

Finally, some factors predisposing to pneumonia in human populations are difficult to study in mice due to limitations inherent to this system of experimentation. Patients in intensive care units (ICUs) are particularly susceptible to nosocomial pneumonias, but the ICU environment has not been fully replicated for mice. The small size of mice coupled with the high cost of intensive care likely prohibit such a development, so only select influences of the ICU on microbial exposures and host responses of ICU patients (e.g., short-term mechanical ventilation; Ref. 23) can be elucidated using experimental studies of mice. Epidemiology studies demonstrate that elevated air pollution increases pneumonia hospitalizations and pneumonia deaths (68, 98, 108, 140) due to small increases in risk spread across large populations (i.e., everyone breathing). Delivering appropriate air pollution challenges to extremely large numbers of mice may be essential for reliably replicating this finding in the laboratory, which may prove unfeasible. Unfortunately, experimental infections of mice may be ineffective for addressing some of the important questions related to the biology of pneumonia.

Comparisons of pneumonias in humans and pneumonias in mice. Overall, there are far more similarities than differences when comparing pneumonias in humans and pneumonias in mice. Both fundamentally involve the same process, the accumulation of pus, a protein-rich exudate containing neutrophils, in the lungs (Figs. 1 and 3). Some similarities will be highlighted briefly here as examples of how studies of experimental pneumonia in mice are relevant to pneumonia in human patients.

Many pneumonias are opportunistic infections, and patients with deficiencies in immune functions are predisposed to infection. Mice with comparable immunodeficiencies are also predisposed to lung infection. For example, human patients with neutropenia of diverse etiologies are susceptible to lung infections, and experimentally induced neutropenia in mice predisposes them to lung infection (69, 121, 125, 127). Similarly, CD4+ T cell depletion in mice renders them susceptible to the same types of lung infections as those that develop in human patients with decreased CD4+ T cells due to HIV/AIDS (65, 111). In addition to direct immunodeficiencies, more complex states of indirect immunocompromise show consistent effects on lung susceptibility to infections in humans and in mice as illustrated with the following examples: respiratory viral infections associate with secondary bacterial pneumonias in humans, and mice with experimental respiratory virus infections have increased susceptibility to bacterial pneumonia (15, 66); alcohol abuse predisposes human patients to bacterial pneumonia, and both acute alcohol intoxication and chronic alcohol exposure are sufficient to compromise pulmonary host defenses in mice (37, 82); obesity is a risk factor for community-acquired pneumonia among humans, and mice rendered obese by leptin targeting have defective innate immune responses to microbes in their lungs (5, 61). These are just a few of the many examples indicating that experimental lung infections in mice model pneumonia in human patients.

Although some differences between species were highlighted above, molecular mechanisms mediating responses during lung infection in mice and humans appear shared more often than disparate. A few examples are listed here. Patients with chronic granulomatous disease due to mutations in the genes for NADPH oxidase components are predisposed to lung infections, and mice in which NADPH oxidase is targeted by genetic engineering show similar susceptibilities (88). Histopathology from humans with leukocyte adhesion deficiency type I resulting from a mutation in the gene for CD18 suggests that neutrophils may use CD18-independent pathways for emigration in the infected lung more than in the skin or soft tissues (40), and mice with CD18 targeted by genetic engineering or blocked by neutralizing antibodies demonstrate that microbial stimuli can induce CD18-independent neutrophil recruitment in the lungs whereas emigration in the skin shows stronger requirements for this adhesion molecule (74, 92). Studies with mice delineated the immune responses triggered by TLR4 stimulation with diverse microbes (52, 89), and polymorphisms in the gene for TLR4 associate with lung infections in human patients (41, 120). The NF-{kappa}B protein p50 is essential to preventing lung injury during experimental pneumonia in mice (76), and a recent study suggests that polymorphisms in the human gene for p50 predispose patients to lung injury (1). These examples illustrate only a few of many factors that are essential to the outcome of pneumonia and consistently apply to both humans and mice.

Conclusion. Pneumonia is an important public health problem, and the biology of pneumonia must be better understood to diminish the burden of this disease. Mouse models are a very useful tool, but (as with any tool) the limitations must be carefully considered in designing and interpreting experiments. Discoveries from mouse models are already providing valuable insights into the biology of pneumonia and have the potential to further direct future medical approaches to patients with pneumonia.


    GRANTS
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 
This study was supported by National Institutes of Health Grants HL-68153, HL-79392, HL-073996, and AI-05714.


    FOOTNOTES
 

Address for reprint requests and other correspondence: J. P. Mizgerd, Dept. of Environmental Health, 665 Huntington Ave., Building I Rm. 301, Boston, MA 02115 (e-mail: jmizgerd{at}hsph.harvard.edu)


    REFERENCES
 TOP
 ABSTRACT
 THE FIRST PRACTICAL...
 THE NEXT PRACTICAL...
 THE BIG CONCERN: A...
 OTHER WAYS IN WHICH...
 GRANTS
 REFERENCES
 

  1. Adamzik M, Frey UH, Rieman K, Sixt S, Beiderlinden M, Siffert W, Peters J. Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome. Intensive Care Med 33: 1199–1203, 2007.[CrossRef][Medline]
  2. An CL, Gigliotti F, Harmsen AG. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing: growth of P. carinii f. sp. muris and host immune response. Infect Immun 71: 2065–2070, 2003.[Abstract/Free Full Text]
  3. Andersen-Nissen E, Smith KD, Bonneau R, Strong RK, Aderem A. A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. J Exp Med 204: 393–403, 2007.[Abstract/Free Full Text]
  4. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 281: 61–66, 1999.[Abstract/Free Full Text]
  5. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 160: 3082–3088, 2000.[Abstract/Free Full Text]
  6. Bakker-Woudenberg IA. Experimental models of pulmonary infection. J Microbiol Methods 54: 295–313, 2003.[CrossRef][Web of Science][Medline]
  7. Bal HS, Ghoshal NG. Morphology of the terminal bronchiolar region of common laboratory mammals. Lab Anim 22: 76–82, 1988.[Abstract/Free Full Text]
  8. Beeching NJ, Dance DA, Miller AR, Spencer RC. Biological warfare and bioterrorism. BMJ 324: 336–339, 2002.[Free Full Text]
  9. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45: 3474–3481, 2001.[Abstract/Free Full Text]
  10. Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 11: 13–33, 1976.[Medline]
  11. Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 120: 1325–1373, 1979.[Web of Science][Medline]
  12. Brieland J, Freeman P, Kunkel R, Chrisp C, Hurley M, Fantone J, Engleberg C. Replicative Legionella pneumophila lung infection in intratracheally inoculated A/J mice. Am J Pathol 145: 1537–1546, 1994.[Abstract]
  13. Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Benjamin WH Jr. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188: 339–348, 2003.[CrossRef][Web of Science][Medline]
  14. Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 83: 309–336, 2003.[Abstract/Free Full Text]
  15. Cate TR. Impact of influenza and other community-acquired viruses. Semin Respir Infect 13: 17–23, 1998.[Medline]
  16. Chatziioannou AF. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc Am Thorac Soc 2: 533–536, 510–511, 2005.
  17. Cox CD. Passage of Pseudomonas aeruginosa in compromised mice. Infect Immun 26: 118–124, 1979.[Abstract/Free Full Text]
  18. Davis IC, Sullender WM, Hickman-Davis JM, Lindsey JR, Matalon S. Nucleotide-mediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol 286: L112–L120, 2004.[Abstract/Free Full Text]
  19. Davis JK, Thorp RB, Parker RF, White H, Dziedzic D, D'Arcy J, Cassell GH. Development of an aerosol model of murine respiratory mycoplasmosis in mice. Infect Immun 54: 194–201, 1986.[Abstract/Free Full Text]
  20. de Hennezel L, Debarre S, Ramisse F, Delamanche S, Harf A, Alonso JM, Calvet JH. Plethysmography for the assessment of pneumococcal pneumonia and passive immunotherapy in a mouse model. Eur Respir J 17: 94–99, 2001.[Abstract/Free Full Text]
  21. Delbridge LM, O'Riordan MX. Innate recognition of intracellular bacteria. Curr Opin Immunol 19: 10–16, 2007.[CrossRef][Web of Science][Medline]
  22. DeMaria TF, Kapral FA. Pulmonary infection of mice with Staphylococcus aureus. Infect Immun 21: 114–123, 1978.[Abstract/Free Full Text]
  23. Dhanireddy S, Altemeier WA, Matute-Bello G, O'Mahony DS, Glenny RW, Martin TR, Liles WC. Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Invest 86: 790–799, 2006.[CrossRef][Web of Science][Medline]
  24. Doerschuk CM. Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation 8: 71–88, 2001.[CrossRef][Web of Science][Medline]
  25. Driehuys B, Hedlund LW. Imaging techniques for small animal models of pulmonary disease: MR microscopy. Toxicol Pathol 35: 49–58, 2007.[Abstract/Free Full Text]
  26. Dumoulin A, Mazars E, Seguy N, Gargallo-Viola D, Vargas S, Cailliez JC, Aliouat EM, Wakefield AE, Dei-Cas E. Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 19: 671–678, 2000.[CrossRef][Web of Science][Medline]
  27. Eisenhauer PB, Lehrer RI. Mouse neutrophils lack defensins. Infect Immun 60: 3446–3447, 1992.[Abstract/Free Full Text]
  28. Enninga J, Sansonetti P, Tournebize R. Roundtrip explorations of bacterial infection: from single cells to the entire host and back. Trends Microbiol 15: 483–490, 2007.[Web of Science][Medline]
  29. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2: 820–832, 2004.[CrossRef][Web of Science][Medline]
  30. Francis KP, Yu J, Bellinger-Kawahara C, Joh D, Hawkinson MJ, Xiao G, Purchio TF, Caparon MG, Lipsitch M, Contag PR. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun 69: 3350–3358, 2001.[Abstract/Free Full Text]
  31. Gingles NA, Alexander JE, Kadioglu A, Andrew PW, Kerr A, Mitchell TJ, Hopes E, Denny P, Brown S, Jones HB, Little S, Booth GC, McPheat WL. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun 69: 426–434, 2001.[Abstract/Free Full Text]
  32. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88: 1651–1655, 1991.[Abstract/Free Full Text]
  33. Grabiec A, Meng G, Fichte S, Bessler W, Wagner H, Kirschning CJ. Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides. J Biol Chem 279: 48004–48012, 2004.[Abstract/Free Full Text]
  34. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 155: 722–729, 1995.[Abstract]
  35. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immun 3: 354–359, 2002.[CrossRef]
  36. Haley PJ. Species differences in the structure and function of the immune system. Toxicology 188: 49–71, 2003.[CrossRef][Web of Science][Medline]
  37. Happel KI, Odden AR, Zhang P, Shellito JE, Bagby GJ, Nelson S. Acute alcohol intoxication suppresses the interleukin 23 response to Klebsiella pneumoniae infection. Alcohol Clin Exp Res 30: 1200–1207, 2006.[CrossRef][Web of Science][Medline]
  38. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164: 944–953, 2000.[Abstract/Free Full Text]
  39. Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, Zhou W, Goleniewska K, O'Neal JF, Morrow JD, Durbin RK, Wright PF, Collins RD, Suzutani T, Peebles RS Jr. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol 78: 10303–10309, 2004.[Abstract/Free Full Text]
  40. Hawkins HK, Heffelfinger SC, Anderson DC. Leukocyte adhesion deficiency: clinical and postmortem observations. Pediatr Pathol 12: 119–130, 1992.[Web of Science][Medline]
  41. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc Natl Acad Sci USA 102: 2487–2489, 2005.[Abstract/Free Full Text]
  42. Hickman-Davis JM, O'Reilly P, Davis IC, Peti-Peterdi J, Davis G, Young KR, Devlin RB, Matalon S. Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 282: L944–L956, 2002.[Abstract/Free Full Text]
  43. Hoffman EA, Chon D. Computed tomography studies of lung ventilation and perfusion. Proc Am Thorac Soc 2: 492–498, 506, 2005.[Abstract/Free Full Text]
  44. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 292: 1115–1118, 2001.[Abstract/Free Full Text]
  45. Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 9: 2315–2322, 2007.[CrossRef][Web of Science][Medline]
  46. Jakab GJ, Green GM. The effect of Sendai virus infection on bactericidal and transport mechanisms of the murine lung. J Clin Invest 51: 1989–1998, 1972.[Web of Science][Medline]
  47. Jeffery PK. Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis 128: S14–S20, 1983.[Web of Science][Medline]
  48. Johansson BE, Kilbourne ED. Comparison of intranasal and aerosol infection of mice in assessment of immunity to influenza virus infection. J Virol Methods 35: 109–114, 1991.[CrossRef][Web of Science][Medline]
  49. Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-{kappa}B activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J Immunol 175: 7530–7535, 2005.[Abstract/Free Full Text]
  50. Kimura K, Miyazaki S, Tateda K, Matsumoto T, Tsujimoto S, Yamaguchi K. Factors affecting the course and severity of transnasally induced Staphylococcus aureus pneumonia in mice. J Med Microbiol 48: 1005–1010, 1999.[Abstract/Free Full Text]
  51. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, Beaudet AL, Bennett CF, Doerschuk CM. The role of ICAM-1 in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 97: 2362–2369, 1996.[Web of Science][Medline]
  52. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immun 1: 398–401, 2000.[CrossRef][Web of Science]
  53. LaForce FM, Boose DS. A radiolabel method for measuring pulmonary clearance of intratracheal bacterial challenges. J Lab Clin Med 111: 158–165, 1988.[Web of Science][Medline]
  54. Larson EW, Dominik JW, Rowberg AH, Higbee GA. Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect Immun 13: 438–447, 1976.[Abstract/Free Full Text]
  55. Laurenzi GA, Berman L, First M, Kass EH. A quantitative study of the deposition and clearance of bacteria in the murine lung. J Clin Invest 43: 759–768, 1964.[CrossRef][Web of Science][Medline]
  56. Lawrence RM, Huston AC, Hoeprich PD. Reproducible method for induction of pulmonary coccidioidomycosis in mice. J Infect Dis 135: 117–119, 1977.[Web of Science][Medline]
  57. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747–1757, 2006.[CrossRef][Web of Science][Medline]
  58. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci USA 103: 9988–9992, 2006.[Abstract/Free Full Text]
  59. Lu W, Hisatsune A, Koga T, Kato K, Kuwahara I, Lillehoj EP, Chen W, Cross AS, Gendler SJ, Gewirtz AT, Kim KC. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J Immunol 176: 3890–3894, 2006.[Abstract/Free Full Text]
  60. Magalhaes JG, Philpott DJ, Nahori MA, Jehanno M, Fritz J, Le Bourhis L, Viala J, Hugot JP, Giovannini M, Bertin J, Lepoivre M, Mengin-Lecreulx D, Sansonetti PJ, Girardin SE. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep 6: 1201–1207, 2005.[CrossRef][Web of Science][Medline]
  61. Mancuso P, Gottschalk A, Phare SM, Peters-Golden M, Lukacs NW, Huffnagle GB. Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. J Immunol 168: 4018–4024, 2002.[Abstract/Free Full Text]
  62. Maris NA, Dessing MC, de Vos AF, Bresser P, van der Zee JS, Jansen HM, Spek CA, van der Poll T. Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin. Eur Respir J 28: 622–626, 2006.[Abstract/Free Full Text]
  63. Mase M, Tanimura N, Imada T, Okamatsu M, Tsukamoto K, Yamaguchi S. Recent H5N1 avian influenza A virus increases rapidly in virulence to mice after a single passage in mice. J Gen Virol 87: 3655–3659, 2006.[Abstract/Free Full Text]
  64. Matute-Bello G, Frevert CW, Liles WC, Nakamura M, Ruzinski JT, Ballman K, Wong WA, Vathanaprida C, Martin TR. Fas/Fas ligand system mediates epithelial injury, but not pulmonary host defenses, in response to inhaled bacteria. Infect Immun 69: 5768–5776, 2001.[Abstract/Free Full Text]
  65. McFadden DC, Powles MA, Smith JG, Flattery AM, Bartizal K, Schmatz DM. Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice. Infect Immun 62: 4887–4892, 1994.[Abstract/Free Full Text]
  66. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 74: 6707–6721, 2006.[Abstract/Free Full Text]
  67. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 170: 5165–5175, 2003.[Abstract/Free Full Text]
  68. Medina-Ramon M, Zanobetti A, Schwartz J. The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. Am J Epidemiol 163: 579–588, 2006.[Abstract/Free Full Text]
  69. Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 163: 6086–6094, 1999.[Abstract/Free Full Text]
  70. Mizgerd JP. Lung infection–a public health priority. PLoS Med 3: e76, 2006.[CrossRef][Medline]
  71. Mizgerd JP. Mechanisms of disease: acute lower respiratory infection. N Engl J Med. In press.
  72. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol 14: 123–132, 2002.[CrossRef][Web of Science][Medline]
  73. Mizgerd JP, Horwitz BH, Quillen HC, Scott ML, Doerschuk CM. Effects of CD18-deficiency on the emigration of murine neutrophils during pneumonia. J Immunol 163: 995–999, 1999.[Abstract/Free Full Text]
  74. Mizgerd JP, Kubo H, Kutkoski GJ, Bhagwan SD, Scharffetter-Kochanek K, Beaudet AL, Doerschuk CM. Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18-deficient mice. J Exp Med 186: 1357–1364, 1997.[Abstract/Free Full Text]
  75. Mizgerd JP, Lupa MM, Hjoberg J, Vallone JC, Warren HB, Butler JP, Silverman ES. Roles for early response cytokines during Escherichia coli pneumonia revealed by mice with combined deficiencies of all signaling receptors for TNF and IL-1. Am J Physiol Lung Cell Mol Physiol 286: L1302–L1310, 2004.[Abstract/Free Full Text]
  76. Mizgerd JP, Lupa MM, Kogan MS, Warren HB, Kobzik L, Topulos GP. Nuclear factor-kB p50 limits inflammation and prevents lung injury during Escherichia coli pneumonia. Am J Respir Crit Care Med 168: 810–817, 2003.[Abstract/Free Full Text]
  77. Mizgerd JP, Meek BB, Kutkoski GJ, Bullard DC, Beaudet AL, Doerschuk CM. Selectins and neutrophil traffic: margination and Streptococcus pneumoniae-induced emigration in murine lungs. J Exp Med 184: 639–645, 1996.[Abstract/Free Full Text]
  78. Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB Jr, Nauseef WM, Dupuy C, Banfi B. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 175: 174–183, 2007.[Abstract/Free Full Text]
  79. Mueller M, Postius S, Thimm JG, Gueinzius K, Muehldorfer I, Hermann C. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines. Immunobiology 209: 599–608, 2004.[CrossRef][Web of Science][Medline]
  80. Murray JF. The Normal Lung. Philadelphia, PA: Saunders, 1986.
  81. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol 2: 205–209, 2002.[CrossRef][Web of Science][Medline]
  82. Onofrio JM, Toews GB, Lipscomb MF, Pierce AK. Granulocyte-alveolar macrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis 127: 335–341, 1983.[Web of Science][Medline]
  83. Oshikawa K, Sugiyama Y. Gene expression of Toll-like receptors and associated molecules induced by inflammatory stimuli in the primary alveolar macrophage. Biochem Biophys Res Commun 305: 649–655, 2003.[CrossRef][Web of Science][Medline]
  84. Pack RJ, Al-Ugaily LH, Morris G. The cells of the tracheobronchial epithelium of the mouse: a quantitative light and electron microscope study. J Anat 132: 71–84, 1981.[Web of Science][Medline]
  85. Parker JC, Townsley MI. Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol 286: L231–L246, 2004.[Abstract/Free Full Text]
  86. Plopper CG. Comparative morphologic features of bronchiolar epithelial cells. The Clara cell. Am Rev Respir Dis 128: S37–S41, 1983.[Web of Science][Medline]
  87. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, Dinauer MC. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 9: 202–209, 1995.[CrossRef][Web of Science][Medline]
  88. Poltorak A, He X, Smirnova I, Liu M, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085–2088, 1998.[Abstract/Free Full Text]
  89. Powles MA, McFadden DC, Pittarelli LA, Schmatz DM. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect Immun 60: 1397–1400, 1992.[Abstract/Free Full Text]
  90. Prince AS, Mizgerd JP, Wiener-Kronish J, Bhattacharya J. Cell signaling underlying the pathophysiology of pneumonia. Am J Physiol Lung Cell Mol Physiol 291: L297–L300, 2006.[Abstract/Free Full Text]
  91. Qin L, Quinlan WM, Doyle NA, Graham L, Sligh JE, Takei F, Beaudet AL, Doerschuk CM. The roles of CD11/CD18 and ICAM-1 in acute Pseudomonas aeruginosa-induced pneumonia in mice. J Immunol 157: 5016–5021, 1996.[Abstract]
  92. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23: 375–378, 2002.[CrossRef][Web of Science][Medline]
  93. Reznik GK. Comparative anatomy, physiology, and function of the upper respiratory tract. Environ Health Perspect 85: 171–176, 1990.[CrossRef][Web of Science][Medline]
  94. Ritman EL. Micro-computed tomography of the lungs and pulmonary-vascular system. Proc Am Thorac Soc 2: 477–480, 501, 2005.[Abstract/Free Full Text]
  95. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3: e5, 2007.
  96. Rose RM, Crumpacker C, Waner JL, Brain JD. Murine cytomegalovirus pneumonia. Description of a model and investigation of pathogenesis. Am Rev Respir Dis 125: 568–573, 1982.[Web of Science][Medline]
  97. Rossi G, Vigotti MA, Zanobetti A, Repetto F, Gianelle V, Schwartz J. Air pollution and cause-specific mortality in Milan, Italy, 1980–1989. Arch Environ Health 54: 158–164, 1999.[Web of Science][Medline]
  98. Ruppert D, Jakab GJ, Sylwester DL, Green GM. Sources of variance in the measurement of intrapulmonary killing of bacteria. J Lab Clin Med 87: 544–558, 1976.[Web of Science][Medline]
  99. Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc 2: 537–540, 511–532, 2005.[Abstract/Free Full Text]
  100. Sadikot RT, Zeng H, Yull FE, Li B, Cheng DS, Kernodle DS, Jansen ED, Contag CH, Segal BH, Holland SM, Blackwell TS, Christman JW. p47(phox) Deficiency impairs NF-kappaB activation and host defense in Pseudomonas pneumonia. J Immunol 172: 1801–1808, 2004.[Abstract/Free Full Text]
  101. Saladino RA, Stack AM, Fleisher GR, Thompson CM, Briles DE, Kobzik L, Siber GR. Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats. Infect Immun 65: 4701–4704, 1997.[Abstract]
  102. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 117: 969–977, 2006.[CrossRef][Web of Science][Medline]
  103. Schneemann M, Schoeden G. Macrophage biology and immunology: man is not a mouse. J Leukoc Biol 81: 579, 2007.[Free Full Text]
  104. Schurr JR, Young E, Byrne P, Steele C, Shellito JE, Kolls JK. Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect Immun 73: 532–545, 2005.[Abstract/Free Full Text]
  105. Schuster DP, Kozlowski J, Hogue L. Imaging lung inflammation in a murine model of Pseudomonas infection: a positron emission tomography study. Exp Lung Res 29: 45–57, 2003.[CrossRef][Web of Science][Medline]
  106. Schutte BC, McCray PB Jr. β-Defensins in lung host defense. Annu Rev Physiol 64: 709–748, 2002.[CrossRef][Web of Science][Medline]
  107. Schwartz J. Total suspended particulate matter and daily mortality in Cincinnati, Ohio. Environ Health Perspect 102: 186–189, 1994.[Web of Science][Medline]
  108. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol 175: 3244–3251, 2005.[Abstract/Free Full Text]
  109. Shapiro SD. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur Respir J 29: 375–378, 2007.[Abstract/Free Full Text]
  110. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 85: 1686–1693, 1990.[Web of Science][Medline]
  111. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118–130, 2007.[CrossRef][Web of Science][Medline]
  112. Sisson TH, Hansen JM, Shah M, Hanson KE, Du M, Ling T, Simon RH, Christensen PJ. Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. Am J Respir Cell Mol Biol 34: 552–560, 2006.[Abstract/Free Full Text]
  113. Skerrett SJ. Lysozyme in pulmonary host defense: new tricks for an old dog. Am J Respir Crit Care Med 169: 435–436, 2004.[Free Full Text]
  114. Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB. Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 276: L715–L727, 1999.[Abstract/Free Full Text]
  115. Steinbach WJ, Benjamin DK Jr, Trasi SA, Miller JL, Schell WA, Zaas AK, Foster WM, Perfect JR. Value of an inhalational model of invasive aspergillosis. Med Mycol 42: 417–425, 2004.[CrossRef][Web of Science][Medline]
  116. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. "The good, the bad, and the ugly". The role of chemokines in models of human disease. J Immunol 156: 3583–3586, 1996.[Web of Science][Medline]
  117. Su X, Robriquet L, Folkesson HG, Matthay MA. Protective effect of endogenous β-adrenergic tone on lung fluid balance in acute bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 290: L769–L776, 2006.[Abstract/Free Full Text]
  118. Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 81: 2736–2744, 2007.[Abstract/Free Full Text]
  119. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, Oron A, Itskovich S, Ballin A, Houri S, Beigelman A, Lider O, Rechavi G, Amariglio N. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189: 2057–2063, 2004.[CrossRef][Web of Science][Medline]
  120. Tateda K, Moore TA, Deng JC, Newstead MW, Zeng X, Matsukawa A, Swanson MS, Yamaguchi K, Standiford TJ. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia. J Immunol 166: 3355–3361, 2001.[Abstract/Free Full Text]
  121. Toews GB. Determinants of bacterial clearance from the lower respiratory tract. Semin Respir Infect 1: 68–78, 1986.[Medline]
  122. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 120: 559–566, 1979.[Web of Science][Medline]
  123. Tournebize R, Doan BT, Dillies MA, Maurin S, Beloeil JC, Sansonetti PJ. Magnetic resonance imaging of Klebsiella pneumoniae-induced pneumonia in mice. Cell Microbiol 8: 33–43, 2006.[CrossRef][Web of Science][Medline]
  124. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 68: 4289–4296, 2000.[Abstract/Free Full Text]
  125. Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, Chen GH, Standiford TJ. Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun 65: 1870–1875, 1997.[Abstract]
  126. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solorzano A, Van Rooijen N, Katz JM, Basler CF. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 79: 14933–14944, 2005.[Abstract/Free Full Text]
  127. Tyler WS. Comparative subgross anatomy of lungs. Pleuras, interlobular septa, and distal airways. Am Rev Respir Dis 128: S32–S36, 1983.[Web of Science][Medline]
  128. Uematsu S, Jang MH, Chevrier N, Guo Z, Kumagai Y, Yamamoto M, Kato H, Sougawa N, Matsui H, Kuwata H, Hemmi H, Coban C, Kawai T, Ishii KJ, Takeuchi O, Miyasaka M, Takeda K, Akira S. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c(+) lamina propria cells. Nat Immun 7: 868–874, 2006.[CrossRef][Web of Science]
  129. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 174: 994–1000, 1996.[Web of Science][Medline]
  130. Vestereng VH, Bishop LR, Hernandez B, Kutty G, Larsen HH, Kovacs JA. Quantitative real-time polymerase chain-reaction assay allows characterization of pneumocystis infection in immunocompetent mice. J Infect Dis 189: 1540–1544, 2004.[CrossRef][Web of Science][Medline]
  131. Ward CL, Dempsey MH, Ring CJ, Kempson RE, Zhang L, Gor D, Snowden BW, Tisdale M. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol 29: 179–188, 2004.[CrossRef][Web of Science][Medline]
  132. Weibel ER, Hsia CC, Ochs M. How much is there really? Why stereology is essential in lung morphometry. J Appl Physiol 102: 459–467, 2007.[Abstract/Free Full Text]
  133. Whitsett JA, Perl AK. Conditional control of gene expression in the respiratory epithelium: a cautionary note. Am J Respir Cell Mol Biol 34: 519–520, 2006.[Free Full Text]
  134. Wiles S, Hanage WP, Frankel G, Robertson B. Modelling infectious disease–time to think outside the box? Nat Rev Microbiol 4: 307–312, 2006.[CrossRef][Web of Science][Medline]
  135. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, Berger K, Mitchell TJ, de los Toyos JR, Rosseau S, Suttorp N, Schutte H. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 34: 1947–1954, 2006.[CrossRef][Web of Science][Medline]
  136. Wyde PR, Couch RB, Mackler BF, Cate TR, Levy BM. Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect Immun 15: 221–229, 1977.[Abstract/Free Full Text]
  137. Yang ZP, Kuo CC, Grayston JT. A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect Immun 61: 2037–2040, 1993.[Abstract/Free Full Text]
  138. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203: 1447–1458, 2006.[Abstract/Free Full Text]
  139. Zanobetti A, Schwartz J. Air pollution and emergency admissions in Boston, MA. J Epidemiol Community Health 60: 890–895, 2006.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Cai, R. L. Zemans, S. K. Young, G. S. Worthen, and S. Jeyaseelan
Myeloid Differentiation Protein-2-Dependent and -Independent Neutrophil Accumulation during Escherichia coli Pneumonia
Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 701 - 709.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Craig, J. Mai, S. Cai, and S. Jeyaseelan
Neutrophil Recruitment to the Lungs during Bacterial Pneumonia
Infect. Immun., February 1, 2009; 77(2): 568 - 575.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Eckle, L. Fullbier, A. Grenz, and H. K. Eltzschig
Usefulness of pressure-controlled ventilation at high inspiratory pressures to induce acute lung injury in mice
Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L718 - L724.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. Matute-Bello, C. W. Frevert, and T. R. Martin
Animal models of acute lung injury
Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L379 - L399.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/3/L387    most recent
00330.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mizgerd, J. P.
Right arrow Articles by Skerrett, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mizgerd, J. P.
Right arrow Articles by Skerrett, S. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.